Home

PERMA-FIX ENVIRONMENTAL SERVICES PROVIDES FURTHER UPDATES ON PATENT-PENDING PROCESS FOR DESTRUCTION OF PFAS COMPOUNDS

TW's Take: this is a great opportunity for PESI and we look forward to seeing what kind of revenues can be generated by this...

Mind the Gap…Micro Performance Continues to Suffer

This week we had a chance to interview Dr. Harlan Weisman, the CEO of TFF Pharma (TFFP). Dr. Weisman related the current travails at...

TFF Pharma…An Interview With The CEO

Despite turning the company around operationally, shares of TFF Pharma (TFFP) have fallen dramatically since Dr. Harlan Weisman took over the reins as CEO...

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American...

TW's Take: good data as INAB continues to show efficacy in a very difficult disease. 92% of evaluable patients treated with INB-200 for glioblastoma...

Cautious on The Market

For pre-revenue companies, times are tough. Funding remains incredibly hard to come by and, for those who display any weakness, the markets are simply...

Aeluma Wins Another Funding Award from the Office of Secretary of Defense

TW's Take: more positive execution on orders that prove the technology while helping keep the burn low while we await the big mobile and...

June Gloom

In San Diego, one might think that June would be one of the best months for weather. You would be partially right. Almost every...

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations...

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program...

TW's Take: while this won't result in revenue any time soon, it's further proof of the technology. As TAC moves into its pivotal trial,...

Perma-Fix Announces Pricing of Approximately $20 Million Registered Direct Offering

TW's Take: this funding, while surprising to the market, should enable them to rapidly develop their PFAS solution; a very timely area of focus. ATLANTA,...

TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical...

TW's Take: Further proof of the potential for the Thin Film Freezing platform technology. Another shot on goal and this one paid for through...

Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

TW's Take: This therapy has the potential to be worth billions of dollars to Anixa and we could be getting results later this year... ...

It’s Getting Hot

This weeks newsletter comes from the Valley of the Sun. It's hot already in Phoenix, where they are currently in a stretch of 100+...

TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for...

TW's Take: more outstanding results from TAC as this drug has all the makings of being a best-in-class blockbuster within a couple years. Now,...

Sell in May and Go Away

In March, I wrote the following.. Markets are nothing if not forward looking. Typically, the start discounting events six months in advance. With election day...

PERMA-FIX REPORTS FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE FOR THE FIRST QUARTER OF 2024

TW's Take: a decent quarter but the stage is set for a great last three months of 2024.  ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Perma-Fix...

QUEST RESOURCE HOLDING CORPORATION REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

TW's Take: strong execution sets the stage for continued growth in the business and in the stock price.  Double-Digit Growth in Gross Profit Resulting...

Premium Subscriber Update, May 8, 2024

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines

TW's Take: quite a positive step as partnering with the renowned Cleveland Clinic on additional vaccines speaks to how well the current trials are...

More Chatter on Financings…and Other Weekend Musings

Last week's topic of conversation was INmune Bio (INMB) and how they had pulled off a very high quality financing. It had solid investors...

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.